Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

Ischemia Testing Foretells Prognosis in Diabetic Patients with Asymptomatic CAD

Caitlin E. Cox

October 03, 2014

News Daily News

Hybrid Revascularization a Promising Option for Diabetic Patients

L.A. McKeown

July 24, 2014

News Daily News

SES Show Advantage Over ZES, PES for Diabetic Patients

Yael L. Maxwell

June 20, 2013

News Conference News AHA 2012

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Jason Kahn

November 11, 2012

News Daily News

PCI, Surgery Show Similar Long-term Mortality in Diabetic, Nondiabetic Patients

L.A. McKeown

August 15, 2012

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

Advertisement

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

Ischemia Testing Foretells Prognosis in Diabetic Patients with Asymptomatic CAD

Hybrid Revascularization a Promising Option for Diabetic Patients

SES Show Advantage Over ZES, PES for Diabetic Patients

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

PCI, Surgery Show Similar Long-term Mortality in Diabetic, Nondiabetic Patients

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content